# SENSOR: Study to Investigate Cinacalcet Treatment in Haemodialysis Patients With Secondary Hyperparathyroidism

> **NCT00117052** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 673 (actual)

## Conditions studied

- Secondary Hyperparathyroidism
- End Stage Renal Disease

## Interventions

- **DRUG:** cinacalcet

## Key facts

- **NCT ID:** NCT00117052
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-09
- **Primary completion:** 2005-11
- **Final completion:** 2006-02
- **Target enrollment:** 673 (ACTUAL)
- **Last updated:** 2013-05-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00117052

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00117052, "SENSOR: Study to Investigate Cinacalcet Treatment in Haemodialysis Patients With Secondary Hyperparathyroidism". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00117052. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*